Based on our present results of increasing resistance of anti-EGFR-sensitive ovarian cancer cells to cetuximab by anti-EGFR TKI sensitization, we further examined whether sensitivity of ovarian cancer cells to death receptor ligands was impaired by anti-EGFR TKI sensitization. Here, EGFR is linked to ovarian cancer.